Varex Imaging (NASDAQ:VREX – Get Free Report) CFO Shubham Maheshwari sold 130,000 shares of Varex Imaging stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $18.46, for a total value of $2,399,800.00. Following the transaction, the chief financial officer owned 139,972 shares of the company’s stock, valued at $2,583,883.12. This trade represents a 48.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Varex Imaging Stock Performance
Shares of Varex Imaging stock opened at $18.47 on Wednesday. The company has a market cap of $777.59 million, a PE ratio of 35.52 and a beta of 0.96. Varex Imaging has a 52 week low of $9.09 and a 52 week high of $18.63. The business has a 50 day moving average price of $15.11 and a 200-day moving average price of $12.40. The company has a quick ratio of 1.53, a current ratio of 3.38 and a debt-to-equity ratio of 0.64.
Varex Imaging (NASDAQ:VREX – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.10. Varex Imaging had a return on equity of 9.19% and a net margin of 2.55%.The company had revenue of $210.50 million for the quarter, compared to analysts’ expectations of $215.50 million. Equities analysts anticipate that Varex Imaging will post 1.04 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Varex Imaging
Analyst Ratings Changes
VREX has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Varex Imaging from a “hold” rating to a “buy” rating in a research note on Saturday, July 4th. Weiss Ratings upgraded shares of Varex Imaging from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 26th. Zacks Research downgraded shares of Varex Imaging from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 27th. CJS Securities downgraded shares of Varex Imaging from an “outperform” rating to a “market perform” rating in a research report on Monday, August 17th. Finally, Oppenheimer lowered shares of Varex Imaging from an “outperform” rating to a “market perform” rating in a research note on Monday, August 10th. Seven research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $16.88.
Get Our Latest Stock Report on Varex Imaging
Varex Imaging Company Profile
Varex Imaging Corporation (NASDAQ: VREX) develops and manufactures X-ray imaging components used by medical, industrial and security equipment manufacturers. Its products are incorporated into systems that support diagnostic imaging, radiation therapy, inspection and threat detection.
The company’s portfolio includes X-ray tubes, digital image detectors, high-voltage generators, image-processing software and other imaging subsystems. These products are used in applications such as computed tomography, radiography, fluoroscopy, mammography, dental and veterinary imaging, as well as industrial non-destructive testing and security screening.
Varex Imaging was established as an independent public company in 2017 through a spin-off from Varian Medical Systems.
See Also
- Five stocks we like better than Varex Imaging
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Varex Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varex Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
